89bio stock reaches 52-week high at $14.97 despite yearly dip

Roche plans to acquire 89bio Inc (ETNB) for an initial $2.4 billion in equity value, potentially increasing to $3.5 billion, primarily for its late-stage drug pegozafermin targeting liver conditions, with the deal expected to close in Q4 2025. This significant acquisition, representing a substantial premium over 89bio's current $1.2 billion market capitalization, has driven ETNB shares to a new 52-week high of $14.97, underscoring the strategic value placed on its clinical pipeline despite varying analyst price targets and a prior annual stock decline.

Analysis

89bio Inc. (ETNB) is being acquired by Roche in a deal valued at approximately $2.4 billion in equity, with potential contingent payments bringing the total to $3.5 billion. This acquisition, centered on ETNB's late-stage liver disease drug pegozafermin, represents a significant premium over the company's current $1.2 billion market capitalization and has driven the stock to a new 52-week high of $14.97. The move comes despite ETNB's prior year-over-year stock decline of 2.53%, suggesting the acquisition is the primary catalyst for the recent price action. Fundamentally, 89bio maintains a strong balance sheet, holding more cash than debt and possessing a high current ratio of 15.19. Analyst sentiment is mixed, reflecting differing valuations of the pipeline; H.C. Wainwright initiated a 'Buy' with a $32.00 price target, while RBC Capital maintains a 'Sector Perform' rating with a recently lowered $11.00 target. The transaction is expected to close in the fourth quarter of 2025, with key clinical data for pegozafermin not anticipated until 2027 and 2028, making the deal's successful completion the central factor for near-term valuation.

Key Decisions for Investors

• The investment case for 89bio has fundamentally shifted to a merger arbitrage play; investors should assess the spread between the current share price and the acquisition value, while monitoring for any regulatory or clinical risks that could impact the deal's closing in Q4 2025.
• Given that Roche's offer represents a substantial premium and the stock now trades above its standalone fair value estimate, further upside is largely capped by the deal terms, including the successful achievement of milestones for contingent payments.
• The wide divergence in analyst price targets is now less relevant than the definitive acquisition price, as post-acquisition, the long-term clinical trial risks and rewards associated with data in 2027-2028 will be borne by Roche, not public shareholders.